There are 3164 resources available
Early, integrated palliative care in older adults with cancer
Presenter: Gabor Liposits
Session: 9th ESMO Designated Centres of Integrated Oncology and Palliative Care session and awards: Specific considerations for integration of oncology and palliative care
Resources:
Slides
Webcast
Q&A and discussion
Session: Oncofertility: What every HCP involved in cancer care should know
Resources:
Webcast
Q&A and discussion with the investigators
Session: ESMO Virtual Plenary revisited
Resources:
Webcast
1722MO - Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)
Presenter: Haibo Qiu
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1146MO - Interim analysis of CABONEN: A multicenter phase II trial investigating cabozantinib in patients with advanced, low proliferative NEN G3
Presenter: Alexander Otto Koenig
Session: Mini oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
LBA19 - Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
Presenter: Heather McArthur
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA62 - Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44
Presenter: Aurélien Lambert
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Abstract
Slides
Webcast
990O - Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
Presenter: Ruth Perets
Session: Proffered paper session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
605O - YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
Presenter: Hongyun Zhao
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Can we expand bladder preservation by optimal use of systemic therapy and biomarkers?
Resources:
Webcast